TT vs URGN · P/E 36, rev $11.32B vs rev $123.4M
Trane Technologies plc (TT) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported TT revenue for 2026-06-30 was $11.32B. Net income was $1.51B. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
TT currently screens at market cap $104.45B and trailing P/E 36.2. URGN currently screens at market cap $1.61B.
Not investment advice. Open the TT and URGN stock pages for the full models.
Not investment advice.